A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW).
Phase of Trial: Phase IV
Latest Information Update: 29 May 2013
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 07 Sep 2007 Status changed from recruiting to completed.
- 15 Nov 2005 New trial record.